Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

SS-31 vs SS-LUP-332: Research Model Comparison

Ischaemia-reperfusion injury Reduces infarct size 15–25%, prevents cytochrome c release, maintains ATP production during reperfusion No protective effect. Insufficient time for transcriptional changes Hours SS-31 is the only viable option Metabolic syndrome mo

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Ischaemia-reperfusion injury
  • Reduces infarct size 15–25%, prevents cytochrome c release, maintains ATP production during reperfusion
  • No protective effect. Insufficient time for transcriptional changes
  • Hours
  • SS-31 is the only viable option
  • Metabolic syndrome models
  • No effect on insulin sensitivity, glucose uptake, or mitochondrial density in non-stressed tissue
  • Improves insulin sensitivity 25–40%, increases mitochondrial respiration, shifts substrate utilisation toward fat oxidation
  • 14–21 days
  • SS-LUP-332 addresses the metabolic root cause
  • Exercise performance enhancement
  • Modest improvements (8–12%) only when combined with actual training stimulus
  • 40–50% improvement in untrained animals, mimics training adaptations at molecular level
  • 10–14 days
  • SS-LUP-332 shows stronger standalone effect
  • Neurodegenerative disease models
  • Mixed results. Mitochondrial protection evident, but poor BBB penetration limits CNS delivery
  • Untested in CNS models due to uncertain brain penetration
  • N/A
  • Neither peptide has strong CNS translational data
  • Cardiac dysfunction (chronic heart failure)
  • Failed primary endpoints in Phase 3 trials despite mitochondrial improvements
  • Preclinical data shows increased cardiac output and oxidative capacity in non-ischaemic models
  • 21+ days
  • SS-LUP-332 may address chronic remodelling better, but clinical data lacking
  • Acute mitochondrial toxin exposure
  • Dose-dependent protection against rotenone, antimycin A, oligomycin toxicity
  • No protection. Can't rescue acutely poisoned mitochondria
  • Minutes to hours
  • SS-31 is protective; SS-LUP-332 is not